In this conference update video, hepatologist Prof. Dr Peter R. Galle joins us live from ASCO 2024 to discuss new hepatocellular carcinoma (HCC) clinical trial data from CheckMate 9DW and share his insights into the potential implications for clinical practice.
What could these developments mean for the treatment landscape in HCC?
ASCO 2024 selected HCC abstract
- Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable HCC: First results from CheckMate 9DW.
Galle PR, et al.
Abstract LBA4008, ASCO 2024
Duration 
Language(s)
Downloadable 
5 MIN
Sep 2024 
